Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Massimo Santoro is active.

Publication


Featured researches published by Massimo Santoro.


Journal of Clinical Oncology | 2012

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells; Bruce G. Robinson; Robert F. Gagel; Henning Dralle; James A. Fagin; Massimo Santoro; Eric Baudin; Rossella Elisei; Barbara Jarzab; Jessica Read; Peter Langmuir; Anderson J. Ryan; Martin Schlumberger

PURPOSEnThere is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.nnnPATIENTS AND METHODSnPatients with advanced MTC were randomly assigned in a 2:1 ratio to receive vandetanib 300 mg/d or placebo. On objective disease progression, patients could elect to receive open-label vandetanib. The primary end point was progression-free survival (PFS), determined by independent central Response Evaluation Criteria in Solid Tumors (RECIST) assessments.nnnRESULTSnBetween December 2006 and November 2007, 331 patients (mean age, 52 years; 90% sporadic; 95% metastatic) were randomly assigned to receive vandetanib (231) or placebo (100). At data cutoff (July 2009; median follow-up, 24 months), 37% of patients had progressed and 15% had died. The study met its primary objective of PFS prolongation with vandetanib versus placebo (hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P < .001). Statistically significant advantages for vandetanib were also seen for objective response rate (P < .001), disease control rate (P = .001), and biochemical response (P < .001). Overall survival data were immature at data cutoff (HR, 0.89; 95% CI, 0.48 to 1.65). A final survival analysis will take place when 50% of the patients have died. Common adverse events (any grade) occurred more frequently with vandetanib compared with placebo, including diarrhea (56% v 26%), rash (45% v 11%), nausea (33% v 16%), hypertension (32% v 5%), and headache (26% v 9%).nnnCONCLUSIONnVandetanib demonstrated therapeutic efficacy in a phase III trial of patients with advanced MTC (ClinicalTrials.gov NCT00410761).


Thyroid | 2015

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Samuel A. Wells; Sylvia L. Asa; Henning Dralle; Rossella Elisei; Douglas B. Evans; Robert F. Gagel; Nancy Y. Lee; Andreas Machens; Jeffrey F. Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce G. Robinson; M. Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha H. Shah; Steven G. Waguespack

INTRODUCTIONnThe American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association.nnnMETHODSnThe Task Force identified relevant articles using a systematic PubMed search, supplemented with additional published materials, and then created evidence-based recommendations, which were set in categories using criteria adapted from the United States Preventive Services Task Force Agency for Healthcare Research and Quality. The original guidelines provided abundant source material and an excellent organizational structure that served as the basis for the current revised document.nnnRESULTSnThe revised guidelines are focused primarily on the diagnosis and treatment of patients with sporadic medullary thyroid carcinoma (MTC) and hereditary MTC.nnnCONCLUSIONSnThe Task Force developed 67 evidence-based recommendations to assist clinicians in the care of patients with MTC. The Task Force considers the recommendations to represent current, rational, and optimal medical practice.


Oncogene | 2007

Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Rosa Visone; Pierlorenzo Pallante; Andrea Vecchione; R. Cirombella; Manuela Ferracin; Angelo Ferraro; Stefano Volinia; S. Coluzzi; V. Leone; E. Borbone; Chang Gong Liu; Fabio Petrocca; Giancarlo Troncone; George A. Calin; Aldo Scarpa; C. Colato; Giovanni Tallini; Massimo Santoro; Carlo M. Croce; Alfredo Fusco

Thyroid carcinomas comprise a broad spectrum of tumors with different clinical behaviors. On the one side, there are occult papillary carcinomas (PTC), slow growing and clinically silent, and on the other side, rapidly growing anaplastic carcinomas (ATC), which are among the most lethal human neoplasms. We have analysed the microRNA (miR) profile of ATC in comparison to the normal thyroid using a microarray (miRNACHIP microarray). By this approach, we found an aberrant miR expression profile that clearly differentiates ATC from normal thyroid tissues and from PTC analysed in previous studies. In particular, a significant decrease in miR-30d, miR-125b, miR-26a and miR-30a-5p was detected in ATC in comparison to normal thyroid tissue. These results were further confirmed by northern blots, quantitative reverse transcription–PCR analyses and in situ hybridization. The overexpression of these four miRs in two human ATC-derived cell lines suggests a critical role of miR-125b and miR-26a downregulation in thyroid carcinogenesis, since a cell growth inhibition was achieved. Conversely, no effect on cell growth was observed after the overexpression of miR-30d and miR-30a-5p in the same cells. In conclusion, these data indicate a miR signature associated with ATC and suggest the miR deregulation as an important event in thyroid cell transformation.


Cancer Research | 2005

Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer

Ginesa Garcia-Rostan; Angela M. Costa; Isabel Pereira-Castro; Giuliana Salvatore; Radhames Hernandez; Mario J.A. Hermsem; Agustin Herrero; Alfredo Fusco; José Cameselle-Teijeiro; Massimo Santoro

The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in thyroid carcinomas through the constitutive activation of stimulatory molecules (e.g., Ras) and/or the loss of expression and/or function of the inhibitory PTEN protein that results in Akt activation. Recently, it has been reported that somatic mutations within the PI3K catalytic subunit, PIK3CA, are common (25-40%) among colorectal, gastric, breast, ovarian cancers, and high-grade brain tumors. Moreover, PIK3CA mutations have a tendency to cluster within the helical (exon 9) and the kinase (exon 20) domains. In this study, 13 thyroid cancer cell lines, 80 well-differentiated thyroid carcinomas of follicular (WDFC) and papillary (WDPC) type, and 70 anaplastic thyroid carcinomas (ATC) were investigated, by PCR-direct sequencing, for activating PIK3CA mutations at exons 9 and 20. Nonsynonymous somatic mutations were found in 16 ATC (23%), two WDFC (8%), and one WDPC (2%). In 18 of the 20 ATC cases showing coexisting differentiated carcinoma, mutations, when present, were restricted to the ATC component and located primarily within the kinase domain. Three cell lines of papillary and follicular lineage (K1, K2, and K5) were also found mutated. In addition, activation of Akt was observed in most of the ATC harboring PIK3CA mutations. These findings indicate that mutant PIK3CA is likely to function as an oncogene among ATC and less frequently well-differentiated thyroid carcinomas. The data also argue for a role of PIK3CA targeting in the treatment of ATC patients.


Journal of Biological Chemistry | 2006

Structure and chemical inhibition of the RET tyrosine kinase domain.

Phillip P. Knowles; Judith Murray-Rust; Svend Kjær; Rizaldy P. Scott; Sarah Hanrahan; Massimo Santoro; Carlos F. Ibáñez; Neil Q. McDonald

The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the human RET tyrosine kinase domain and the structure determination of the non-phosphorylated and phosphorylated forms. Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status. In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity. Longer forms of RET containing the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain. Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity. We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474. These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.


Clinical Cancer Research | 2006

BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma

Giuliana Salvatore; Valentina De Falco; Paolo Salerno; Tito Claudio Nappi; Stefano Pepe; Giancarlo Troncone; Francesca Carlomagno; Rosa Marina Melillo; Scott M. Wilhelm; Massimo Santoro

Purpose: Oncogenic conversion of BRAF occurs in ∼44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma. Experimental Design: We used RNA interference to evaluate the effect of BRAF knockdown in the human anaplastic thyroid carcinoma cell lines FRO and ARO carrying the BRAF V600E (V600EBRAF) mutation. We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl)-N-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea], a multikinase inhibitor able to inhibit RAF family kinases in a panel of six V600EBRAF-positive thyroid carcinoma cell lines and in nude mice bearing ARO cell xenografts. Statistical tests were two sided. Results: Knockdown of BRAF by small inhibitory duplex RNA, but not control small inhibitory duplex RNA, inhibited the mitogen-activated protein kinase signaling cascade and the growth of ARO and FRO cells (P < 0.0001). These effects were mimicked by thyroid carcinoma cell treatment with BAY 43-9006 (IC50 = 0.5-1 μmol/L; P < 0.0001), whereas the compound had negligible effects in normal thyrocytes. ARO cell tumor xenografts were significantly (P < 0.0001) smaller in nude mice treated with BAY 43-9006 than in control mice. This inhibition was associated with suppression of phospho–mitogen-activated protein kinase levels. Conclusions: BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the V600EBRAF mutation and, therefore, BRAF suppression might have therapeutic potential in V600EBRAF-positive thyroid cancer.


The American Journal of Surgical Pathology | 2000

RET/PTC activation in hyalinizing trabecular tumors of the thyroid.

Mauro Papotti; Marco Volante; Ada Giuliano; Ambrogio Fassina; Alfredo Fusco; Gianni Bussolati; Massimo Santoro; Gennaro Chiappetta

Hyalinizing trabecular tumor (HTT) of the thyroid is a neoplasm of follicular derivation with a histogenesis that is still the subject of debate. Morphologic affinities between HTT and papillary carcinoma, including nuclear pseudoinclusions and grooves, suggest that these tumors may be of similar origin. The authors investigated the relationship between these two types of tumors by assessing HTT for the presence of rearrangements of the proto-oncogene rearranged during transfection (RET) that, in thyroid tumors, are specific for papillary carcinoma. A series of 14 HTTs, including two cases associated with classic papillary carcinoma, was studied by means of immunohistochemistry and reverse transcription–polymerase chain reaction. Seven follicular adenomas with focal hyalinized trabecular areas served as control cases. Three of the 14 HTT cases under consideration displayed rearrangements of RET generating the RET/papillary thyroid carcinoma type 1 (PTC1) oncogene. In another case, RET expression was detected focally by immunohistochemistry alone. Finally, in one mixed HTT–papillary carcinoma sample, RET/PTC1 expression was detected, but only in the papillary component. None of the control follicular adenomas contained rearrangements of RET/PTC. These findings demonstrate that a comparable percentage (28.6%) of HTTs and papillary carcinomas exhibit the same RET proto-oncogene alterations. Thus, HTT may represent the “hyalinizing trabecular” variant of papillary carcinoma rather than a separate entity.


Cancer | 1994

Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers

Nicole Fabien; Alfredo Fusco; Massimo Santoro; Yves Barbier; Paul-Marie Dubois; Christian Paulin

Background. The establishment of cell lines from thyroid carcinomas can provide an in vitro model of oncogenesis. B‐CPAP is a new cell line that has been obtained from a differentiated papillary thyroid carcinoma. The data presented give a broader characterization and expression of tumoral markers of this cell line and identify the differentiated functions that are preserved.


Proceedings of the National Academy of Sciences of the United States of America | 2001

Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway

Gustavo Baldassarre; Monica Fedele; Sabrina Battista; Andrea Vecchione; Andres J. Klein-Szanto; Massimo Santoro; Thomas A. Waldmann; Nazli Azimi; Carlo M. Croce; Alfredo Fusco

Rearrangements of the high mobility group protein I-C (HMGI-C) gene, consisting in the loss of the carboxyl-terminal tail, have been frequently detected in benign human tumors of mesenchymal origin. We have previously demonstrated that transgenic (TG) mice carrying a truncated HMGI-C construct (HMGI-C/T) exhibit a giant phenotype together with a predominantly abdominal/pelvic lipomatosis. Here, we report that HMGI-C/T TG mice develop natural killer (NK)-T/NK cell lymphomas starting from 12 months of age. We found an increased expression of IL-2 and IL-15 proteins and their receptors in these lymphomas, and we demonstrate that HMGI-C/T protein positively regulates their expression in vitro. Therefore, the HMGI-C/T-mediated chronic stimulation of the IL-2/IL-15 pathway could be responsible for the onset of NK-T/NK cell lymphomas in HMGI-C/T TG mice.


Molecular and Cellular Biology | 2001

Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation.

Rosa Marina Melillo; Giovanna Maria Pierantoni; Stefania Scala; Sabrina Battista; Monica Fedele; Antonella Stella; M. C. De Biasio; Gennaro Chiappetta; V. Fidanza; Gianluigi Condorelli; Massimo Santoro; C. M. Croce; Giuseppe Viglietto; Alfredo Fusco

ABSTRACT The high-mobility group I (HMGI) nonhistone chromosomal proteins HMGI(Y) and HMGI-C have been implicated in defining chromatin structure and in regulating the transcription of several genes. These proteins have been implicated in adipocyte homeostasis: a severe deficiency of fat tissue is found in mice with targeted disruption of the HMGI-C locus, and lipomagenesis in humans is frequently associated with somatic mutations of HMGI genes. The aim of this study was to examine the role of HMGI(Y) proteins in adipocytic cell growth and differentiation. First, we found that differentiation of the preadipocytic 3T3-L1 cell line caused early induction of HMGI(Y) gene expression. Suppression of HMGI(Y) expression by antisense technology dramatically increased the growth rate and impaired adipocytic differentiation in these cells. The process of adipogenic differentiation involves the interplay of several transcription factors, among which is the CCAAT/enhancer-binding protein (C/EBP) family of proteins. These factors are required for the transcriptional activation of adipocyte-specific genes. We also tested the hypothesis that HMGI(Y) might participate in transcriptional control of adipocyte-specific promoters. We found that HMGI(Y) proteins bind C/EBPβ in vivo and in vitro. Furthermore, we show that HMGI(Y) strongly potentiates the capacity of C/EBPβ to transactivate the leptin promoter, an adipose-specific promoter. Taken together, these results indicate that the HMGI(Y) proteins play a critical role in adipocytic cell growth and differentiation.

Collaboration


Dive into the Massimo Santoro's collaboration.

Top Co-Authors

Avatar

Alfredo Fusco

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Gennaro Chiappetta

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Francesca Carlomagno

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Rosa Marina Melillo

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Giuliana Salvatore

Maharaja Sayajirao University of Baroda

View shared research outputs
Top Co-Authors

Avatar

Monica Fedele

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Giancarlo Vecchio

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Giancarlo Troncone

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Giovanni Santelli

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Maria Domenica Castellone

University of Naples Federico II

View shared research outputs
Researchain Logo
Decentralizing Knowledge